Literature DB >> 24202651

Determinants of practice patterns and quality gaps in lung cancer staging and diagnosis.

David E Ost1, Jiangong Niu2, Linda S Elting2, Thomas A Buchholz3, Sharon H Giordano2.   

Abstract

BACKGROUND: Guidelines recommend mediastinal lymph node sampling as the fi rst invasive diagnostic procedure in patients with suspected lung cancer with mediastinal lymphadenopathy without distant metastases.
METHODS: Patients were a retrospective cohort of 15,316 patients with lung cancer with regional spread without metastatic disease in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) or Texas Cancer Registry Medicare-linked databases. Patients were categorized based on the sequencing of invasive diagnostic tests performed: (1) evaluation consistent with guidelines, mediastinal sampling done fi rst; (2) evaluation inconsistent with guidelines, non-small cell lung cancer (NSCLC) present, mediastinal sampling performed but not as part of the fi rst invasive test; (3) evaluation inconsistent with guidelines, NSCLC present, mediastinal sampling never done; and (4) evaluation inconsistent with guidelines, small cell lung cancer. The primary outcome was whether guideline-consistent care was delivered. Secondary outcomes included whether patients with NSCLC ever had mediastinal sampling and use of transbronchial needle aspiration (TBNA) among pulmonologists.
RESULTS: Only 21% of patients had a diagnostic evaluation consistent with guidelines. Only 56% of patients with NSCLC had mediastinal sampling prior to treatment. There was significant regional variability in guideline-consistent care (range, 12%-29%). Guideline-consistent care was associated with lower patient age, metropolitan areas, and if the physician ordering or performing the test was male, trained in the United States, had seen more patients with lung cancer, and was a pulmonologist or thoracic surgeon who had graduated more recently. More recent pulmonary graduates were also more likely to perform TBNA ( P < .001).
CONCLUSIONS: Guideline-consistent care varied regionally and was associated with physician-level factors, suggesting that a lack of effective physician training may be contributing to the quality gaps observed.

Entities:  

Mesh:

Year:  2014        PMID: 24202651      PMCID: PMC4502717          DOI: 10.1378/chest.13-1628

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  Affording endobronchial ultrasound.

Authors:  Scott Manaker; Armin Ernst; Lynne Marcus
Journal:  Chest       Date:  2008-04       Impact factor: 9.410

2.  Endobronchial ultrasound guided transbronchial needle aspiration of mediastinal lymph nodes for lung cancer staging: a projected cost analysis.

Authors:  M E J Callister; A Gill; W Allott; P K Plant
Journal:  Thorax       Date:  2008-04       Impact factor: 9.139

3.  Practice guidelines for non-small cell lung cancer.

Authors:  R Cameron; J Fringer; C Taylor; C R Gilden; R A Figlin
Journal:  Cancer J Sci Am       Date:  1996 May-Jun

4.  Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study.

Authors:  Robert James Cerfolio; Ayesha S Bryant; Mohamad A Eloubeidi
Journal:  Chest       Date:  2006-12       Impact factor: 9.410

5.  Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Frank C Detterbeck; Michael A Jantz; Michael Wallace; Johan Vansteenkiste; Gerard A Silvestri
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

6.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition).

Authors:  Gerard A Silvestri; Michael K Gould; Mitchell L Margolis; Lynn T Tanoue; Douglas McCrory; Eric Toloza; Frank Detterbeck
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

Review 7.  Endobronchial ultrasound in the evaluation of lung cancer: a practical review and cost analysis for the practicing pulmonologist.

Authors:  Mark R Bowling; C David Perry; Robert Chin; Norman Adair; Arjun Chatterjee; John Conforti
Journal:  South Med J       Date:  2008-05       Impact factor: 0.954

8.  ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.

Authors:  Paul De Leyn; Didier Lardinois; Paul E Van Schil; Ramon Rami-Porta; Bernward Passlick; Marcin Zielinski; David A Waller; Tony Lerut; Walter Weder
Journal:  Eur J Cardiothorac Surg       Date:  2007-04-19       Impact factor: 4.191

9.  Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer.

Authors:  Robert J Cerfolio; Ayesha S Bryant
Journal:  Ann Thorac Surg       Date:  2008-08       Impact factor: 4.330

10.  Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.

Authors:  Felix J F Herth; Ralf Eberhardt; Mark Krasnik; Armin Ernst
Journal:  Chest       Date:  2008-02-08       Impact factor: 9.410

View more
  9 in total

1.  Bronchoscopy with endobronchial ultrasound guided transbronchial needle aspiration vs. transthoracic needle aspiration in lung cancer diagnosis and staging.

Authors:  Mark L Munoz; Noah Lechtzin; Qing Kay Li; KoPen Wang; Lonny B Yarmus; Hans J Lee; David J Feller-Kopman
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

2.  Safety and Costs of Endobronchial Ultrasound-Guided Nodal Aspiration and Mediastinoscopy.

Authors:  Francys C Verdial; Kathleen S Berfield; Douglas E Wood; Michael S Mulligan; Joshua A Roth; David O Francis; Farhood Farjah
Journal:  Chest       Date:  2019-10-09       Impact factor: 9.410

3.  Variability in invasive mediastinal staging for lung cancer: A multicenter regional study.

Authors:  Lucas W Thornblade; Douglas E Wood; Michael S Mulligan; Alexander S Farivar; Michal Hubka; Kimberly E Costas; Bahirathan Krishnadasan; Farhood Farjah
Journal:  J Thorac Cardiovasc Surg       Date:  2018-02-09       Impact factor: 5.209

4.  Evaluation of Appropriate Mediastinal Staging among Endobronchial Ultrasound Bronchoscopists.

Authors:  Russell J Miller; Lakshmi Mudambi; Macarena R Vial; Mike Hernandez; George A Eapen
Journal:  Ann Am Thorac Soc       Date:  2017-07

5.  Pretreatment Invasive Nodal Staging in Lung Cancer: Knowledge, Attitudes, and Beliefs Among Academic and Community Physicians.

Authors:  Louise M Henderson; Farhood Farjah; Frank Detterbeck; Robert A Smith; Gerard A Silvestri; M Patricia Rivera
Journal:  Chest       Date:  2021-11-18       Impact factor: 10.262

6.  Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.

Authors:  David E Ost; Jiangong Niu; Hui Zhao; Horiana B Grosu; Sharon H Giordano
Journal:  Chest       Date:  2017-08-31       Impact factor: 9.410

7.  Vascular endothelial growth factor C complements the ability of positron emission tomography to predict nodal disease in lung cancer.

Authors:  Farhood Farjah; David K Madtes; Douglas E Wood; David R Flum; Megan E Zadworny; Rachel Waworuntu; Billanna Hwang; Michael S Mulligan
Journal:  J Thorac Cardiovasc Surg       Date:  2015-08-06       Impact factor: 5.209

8.  Which are the limiting factors in lung tissue sampling and diagnostic accuracy for a new Interventional Pulmonology Unit? From expert consensus-based evidence to results of a new-born Unit.

Authors:  Cristiano Carbonelli; Antonio Rossi; Gianluca Ciliberti; Maria Arcangela Grimaldi; Stefano Notarangelo; Paola Parente; Massimiliano Copetti; Alessandro Zanforlin; Filippo Lococo; Marco Taurchini; Evaristo Maiello; Salvatore De Cosmo; Paolo Graziano
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

9.  An Audit of CT Chest Reports and Their Potential Impact on the Workup of Patients with Suspected Lung Cancer.

Authors:  Andrew Weinstock; Luke Jeagal; Chantal Savard; Jana Taylor; Anne V Gonzalez
Journal:  Can Respir J       Date:  2021-06-05       Impact factor: 2.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.